GLP-RT
COA published
A synthetic triple receptor agonist peptide studied in in-vitro GIP, GLP-1 and glucagon receptor binding research.
From$79.00Select size
5-Amino-1MQ
CAS685079-15-6MEASURED PURITY99.94%
A small-molecule NNMT inhibitor studied in enzyme-inhibition and cellular-metabolism research models.
- Test methods
- HPLC-UV + LC-MS
- Purity target
- 99%+ verified
- Sizes available
- 2
- Availability
- In stock
Select size
Quantity
1
Total
$32.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
Batch SYX-5AMQ5-0826 · Certificate of Analysis available
For Research Use Only. Not for Human Consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
✦ Research Notes
Background & literature
Origin
5-Amino-1MQ is not a peptide — it is a small molecule, a quinolinium compound, and it is in this catalog because of its enzyme target rather than its chemistry. It was developed as a cell-permeable inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosylmethionine to nicotinamide. NNMT sits at an interesting junction: it consumes both a methyl donor and a NAD+ precursor, which connects it to two separate areas of metabolic research.
What has been characterised
Characterised as a small-molecule NNMT inhibitor. The enzyme is the subject of substantial current research: a 2025 Nature paper examined NNMT inhibition in cancer-associated fibroblasts with respect to antitumour immunity, and a 2025 Molecular Cancer paper examined NNMT in EGFR-TKI resistance mechanisms. Note that this literature is about the enzyme target and its biology, largely in cancer models — it is not literature about this specific inhibitor as a product. Cell-culture and animal work. Not FDA-approved for any use.
Sources
- 1.“NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity.” Nature, 2025. PMID 40702186
- 2.“NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer.” Mol Cancer, 2025. PMID 40089784
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Batch releases & restocks
Know when the next batch is tested
We publish an independent certificate for every lot before it ships. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.
Related Compounds
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.